/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Incyte Corporation (INCY) is a Wilmington, Delaware–based global biopharmaceutical company focused on developing and marketing innovative therapies in oncology, immunology, dermatology, and inflammation. Founded in 2002, Incyte has grown into a large-cap biotech with a market cap of $13.3 billion.
INCY is all geared up its fiscal Q2 earnings for 2025 before the market opens on Tuesday, Apr. 29. Prior to this event, analysts project this biopharmaceutical company to report a profit of $1.13 per share, up 155.7% from a loss of $2.03 per share in the year-ago quarter. The company has missed Wall Street's bottom-line estimates in three of the last four quarters, while surpassing on one quarter.